Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$568 Sell
3
-17
-85% -$2.52K ﹤0.01% 2351
2026
Q1
$1.86K Hold
20
﹤0.01% 2149
2025
Q4
$1.61K Hold
20
﹤0.01% 2175
2025
Q3
$1.95K Hold
20
﹤0.01% 2155
2025
Q2
$1.39K Sell
20
-4
-17% -$228 ﹤0.01% 2175
2025
Q1
$1.19K Sell
24
-146
-86% -$9.23K ﹤0.01% 2278
2024
Q4
$11.9K Sell
170
-168
-50% -$14K ﹤0.01% 1774
2024
Q3
$48.1K Buy
338
+66
+24% +$7.72K ﹤0.01% 1583
2024
Q2
$30.3K Buy
272
+188
+224% +$21.7K ﹤0.01% 1489
2024
Q1
$9.37K Sell
84
-221
-72% -$26.3K ﹤0.01% 1458
2023
Q4
$50K Buy
305
+153
+101% +$21.1K ﹤0.01% 932
2023
Q3
$28K Buy
152
+65
+75% +$11.4K ﹤0.01% 1056
2023
Q2
$12K Sell
87
-199
-70% -$28.6K ﹤0.01% 1230
2023
Q1
$23K Sell
286
-250
-47% -$29.4K ﹤0.01% 1313
2022
Q4
$32K Buy
536
+482
+893% +$34K ﹤0.01% 1105
2022
Q3
$3K Buy
54
+47
+671% +$3.04K ﹤0.01% 1659
2022
Q2
$1K Buy
+7
New +$406 ﹤0.01% 1729

Other funds holding ACLS

Blue Trust Inc's ACLS Position: Q2 2026 in Review

Blue Trust Inc reduced its Axcelis (ACLS) stake by 85% in Q2 2026, selling an estimated $2.52K and leaving 3 shares worth $568. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

Blue Trust Inc first reported a position in ACLS in Q2 2022 and has held it in 17 quarters since. The position peaked at $50K in Q4 2023. 439 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Blue Trust Inc held 3 shares of Axcelis worth $568 as of Q2 2026.
  • Blue Trust Inc sold 17 Axcelis shares in Q2 2026, an estimated $2.52K.
  • Axcelis made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2351 holding.
  • Blue Trust Inc first reported a position in Axcelis in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Axcelis position peaked at $50K in Q4 2023.
  • 439 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.